Quadrature Capital’s Tyra Biosciences TYRA Stock Holding History

Quadrature Capital’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-18,203	Closed	-$697K	–	2063
2026 Q1	$697K	Buy	+18,203	New	+$589K	0.01%	680

Other funds holding TYRA

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

APMC

Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Quadrature Capital's TYRA Position: Q2 2026 in Review

Quadrature Capital sold out of Tyra Biosciences (TYRA) in Q2 2026, closing a stake of 18,203 shares — an estimated $697K sold.

Quadrature Capital first reported a position in TYRA in Q1 2026 and held it in 1 quarter. The position peaked at $697K in Q1 2026. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

Quadrature Capital reported no remaining Tyra Biosciences position as of Q2 2026 after selling out during the quarter.
Quadrature Capital sold 18,203 Tyra Biosciences shares in Q2 2026, an estimated $697K.
Quadrature Capital first reported a position in Tyra Biosciences in Q1 2026 and held it in 1 quarter.
Quadrature Capital's Tyra Biosciences position peaked at $697K in Q1 2026.
169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.